{"groups":[{"description":"Patients receive oral anastrozole once daily on days 1-28.\n\nanastrozole: Given orally","id":"FG000","title":"Arm I Anastrozole"},{"description":"Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.\n\nanastrozole: Given orally\n\nfulvestrant: Given intramuscularly","id":"FG001","title":"Arm II Anastrozole and Fulvestrant"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"12"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"8"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"18"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"269"},{"groupId":"FG001","numSubjects":"274"}],"type":"Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"15"}],"type":"Still on treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}],"type":"Delinquent"},{"reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"19"}],"type":"Not protocol specified"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Under review"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"345"},{"groupId":"FG001","numSubjects":"349"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"345"},{"groupId":"FG001","numSubjects":"349"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"707 Patients underwent randomization. 12 were excluded: 9 did not have metastatic disease, 1 had previous chemotherapy, 1 was estrogen-receptor and progesterone-receptor negative, 1 did not undergo chest imaging. In addition, 1 patient withdrew consent.\n\n694 patients were included in the analysis."}